Peregrine Pharmaceuticals, Inc. (PPHM)
-NasdaqCM 1.51 
0.01(0.67%) 2:45PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.50 |
|---|
| Open: | 1.52 |
|---|
| Bid: | 1.50 x 48800 |
|---|
| Ask: | 1.51 x 2800 |
|---|
| 1y Target Est: | 4.75 |
|---|
| Beta: | 1.46 |
|---|
| Next Earnings Date: | 17-Jul-13 |
|---|
| Day's Range: | 1.50 - 1.52 |
|---|
| 52wk Range: | 0.46 - 5.50 |
|---|
| Volume: | 553,140 |
|---|
| Avg Vol (3m): | 2,368,550 |
|---|
| Market Cap: | 207.04M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Has Peregrine Pharmaceuticals Finally Turned The Corner?at Seeking Alpha(Wed, Jun 12)
- Why Peregrine Pharmaceuticals Shares Poppedat Motley Fool(Mon, Jun 3)
- DirecTV Entertains Hulu Bid, Pandora Slides on New Rival, and 3 Other Hot Stocksat Wall St. Cheat Sheet(Mon, Jun 3)
- PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, Jun 3)
- Encouraging Results in Breast and Pancreatic Cancers for Patients Treated With Peregrine's Novel Immunotherapy Bavituximab Presented at ASCOMarketwired(Mon, Jun 3)
- Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated With Peregrine Pharmaceuticals' Novel Immunotherapy BavituximabMarketwired(Mon, Jun 3)
- This Week in Biotechat Motley Fool(Sat, May 25)
- Encouraging News for Peregrine PharmaZacks(Fri, May 24)
- Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapyat Seeking Alpha(Thu, May 23)
- FDA Green Light = Surprise Share Surgeat Motley Fool(Tue, May 21)
- These Winners Couldn't Send the Dow to Another Recordat Motley Fool(Mon, May 20)
- Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trialsat Motley Fool(Mon, May 20)
- Small-cap makes a splash with FDA nod for cancer drugat MarketWatch(Mon, May 20)
- Movers roundup: WPX Energy, PeregrineAP(Mon, May 20)
- Why Peregrine Pharmaceuticals Shares Skyrocketedat Motley Fool(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 10.55 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Apr-13)
: | -0.23 |
|---|
| Quarterly EPS Est
(Apr-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment and diagnosis of cancer and viral infections.
View More